Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback